E-Z-Cat Dry

(Barium)

PreclinicalSmall molecule

BBracco Diagnostics, Inc

E-Z-Cat Dry is one of 6 small molecule programs targeting Head and Neck. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Head and NeckActive, not recruiting

Head and NeckPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Head and Neck

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

2 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

4 3

Keytruda

Merck & Co.

Phase 2

3 4

Botulinum Toxin

MMeshalkin Research Institute of Pathology of Circulation

Phase 3

1 5

Ethyl Chloride

NNYU Langone Health

Preclinical

1 6

E-Z-Cat Dry

BBracco Diagnostics, Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

N/AActive, not recruiting

Head and Neck

NCT02662907

Clinical

Trials by Indication[1]

Oral1 trial

Uniformity of Oral Contrast Material in the Bowel

Completed·UUniversity of California, San Francisco··NCT02542046·900 enrolled

Head and Neck1 trial

Cough, Expiratory Training, and Chronic Aspiration After Head and Neck Radiotherapy

Active, not recruiting·MM.D. Anderson Cancer Center·N/A·NCT02662907·175 enrolled

Regulatory

FDA Approval Timeline[4]

Oct 14, 2016

VARIBAR PUDDING

NDA NDA208844

Jan 3, 2017

E-Z-CAT DRY

NDA NDA208036

May 29, 2020

ENTERO VU 24%

NDA NDA208143

Aug 1, 2025

E-Z-DISK

NDA NDA219840

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Barium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Barium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Barium. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA219840). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Bracco Diagnostics, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBracco Diagnostics, Inc

E-Z-Cat Dry

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Oral1 trial

Head and Neck1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News